GI
NVCT icon

GAMMA Investing’s Nuvectis Pharma NVCT Stock Holding History

GAMMA Investing’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.99K Sell
489
-156
-24% -$1.75K ﹤0.01% 3265
2026
Q1 		$4.99K Buy
645
+474
+277% +$4.06K ﹤0.01% 3362
2025
Q4 		$1.29K Buy
171
+83
+94% +$541 ﹤0.01% 3725
2025
Q3 		$530 Buy
+88
New +$605 ﹤0.01% 3710
2024
Q2 		– Sell
-25
Closed -$205 – 3494
2024
Q1 		$205 Buy
+25
New +$213 ﹤0.01% 3226

Other funds holding NVCT

BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
AWM
Austin Wealth Management Austin, Texas $473M AUM 18.73% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

GAMMA Investing's NVCT Position: Q2 2026 in Review

GAMMA Investing reduced its Nuvectis Pharma (NVCT) stake by 24% in Q2 2026, selling an estimated $1.75K and leaving 489 shares worth $8.99K. The position accounts for ﹤0.01% of the portfolio, ranked #3265.

GAMMA Investing first reported a position in NVCT in Q1 2024 and has held it in 5 quarters since. 9 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • GAMMA Investing held 489 shares of Nuvectis Pharma worth $8.99K as of Q2 2026.
  • GAMMA Investing sold 156 Nuvectis Pharma shares in Q2 2026, an estimated $1.75K.
  • Nuvectis Pharma made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3265 holding.
  • GAMMA Investing first reported a position in Nuvectis Pharma in Q1 2024 and has held it in 5 quarters since.
  • 9 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.